John Fanikos Praises Nathan Connell’s Efforts on Hemophilia Gene Therapy in Boston
John Fanikos, Director of Strategic Initiatives at North American Thrombosis Forum, shared a post on LinkedIn:
“Hemophilia historically has been seen as a ‘royal disease’ because of its occurrence in the royal families of Spain, Germany and Russia.
Today it is known as a genetic disorder where bleeding occurs because of low levels of blood clotting Factor 8 (VIII) or Factor 9 (IX). As simple as a missing gene on a chromosome that provides the blueprint for the protein Factor.
Enter gene therapy.
Kudos to Dr Nathan Connell, who worked feverishly to bring this treatment to the Boston area.
You can hear the treatment results of his first patient on the CBS news and follow his expertise at the Vasculearn Network”
Nathan Connell’s first patient results featured on CBS News.
Follow his expertise on the Vasculearn Network.
Stay informed with Hemostasis Today.
-
Aug 25, 2026, 12:26Rahaf M. Altahan: Diagnosis and Management of Factor XIII Deficiency
-
Aug 25, 2026, 12:20Christodoulos Papadopoulos: Oral Anticoagulation Monotherapy in Chronic Coronary Syndrome
-
Aug 25, 2026, 12:17Ifeanyichukwu Ifechidere: Coagulation Knowledge in Cardiology
-
Aug 25, 2026, 12:14Annie Bauzon: Platelets – The Tiny Cells That Stop You From Bleeding
-
Aug 25, 2026, 12:10Marloes de Kovel: FVIII Exposure With Severe Haemophilia A on Emicizumab Prophylaxis
-
Aug 25, 2026, 11:59What Happens When the Next Generation of Hematologists Looks Elsewhere? – Global Hemophilia Report
-
Aug 25, 2026, 11:54Kimberly Jacobson: MSL Opportunity in Rare Blood and Bleeding Disorders
-
Aug 25, 2026, 11:48GPAS 2026 Advancing Access and Equity in Bleeding Disorders – WFH
-
Aug 25, 2026, 11:41Gregory Lip: Don’t Miss – €1,000 Mechanical Thrombectomy Grant